Biopharma in China

Sven Agten () and Ben Wu ()

in Springer Books from Springer

Date: 2024
ISBN: 978-981-97-1471-1
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Chapters in this book:

The Chinese Healthcare and Pharmaceutical Market: Ignore at Your Own Peril

Sven Agten and Ben Wu

China Regulatory and Legal Reforms: Gateway to Innovation and Global Integration

Sven Agten and Ben Wu

The Golden Age of Chinese Biopharma Sector, 2014–2021: Explosive Growth in a Thriving Ecosystem

Sven Agten and Ben Wu

Innovation in the Chinese Biopharma Sector: From Me-too to First-in-Class

Sven Agten and Ben Wu

The Art of the Biopharma Deal: The China Angle

Sven Agten and Ben Wu

End of the First Cycle, 2022 and Beyond: A Drastic Reset, Increased Challenges But Also New Opportunities

Sven Agten and Ben Wu

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprbok:978-981-97-1471-1

Ordering information: This item can be ordered from
http://www.springer.com/9789819714711

DOI: 10.1007/978-981-97-1471-1

Access Statistics for this book

More books in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().